🧠 Food for thought

Implications, context, and why it matters.

Elisrasib faces head-to-head competition with two approved KRAS G12C drugs showing similar efficacy

• In pretreated non–small cell lung cancer (NSCLC), objective response rates (percentage of patients with meaningful tumor shrinkage) reached 37.1% and 42.9% 1. PFS was 6.8 and 6.5 months 1.
• Adagrasib beat docetaxel in phase 3 KRYSTAL-12, with median PFS of 5.5 months versus 3.8 months, hazard ratio 0.58 2.
• D3 Bio is running trials for elisrasib to seek registration. The funding announcement shared no efficacy or safety data, so investors cannot weigh differentiation, including in brain metastases where adagrasib posted 33.3% intracranial response (tumor shrinkage in brain lesions) 1.
• Approval timing and market fit stay unclear without a head-to-head profile versus approved rivals, one holds FDA accelerated approval 2.

Multi-region KRAS G12C trials create expansion opportunities for diagnostic labs and precision medicine infrastructure

• KRAS G12C mutations appear in about 13% of non-squamous NSCLC, and roughly 45% carry actionable oncogenic drivers (gene alterations that can be matched to specific drugs) that require testing 3.
• Biomarker testing (laboratory analysis to find gene mutations and other markers in a tumor) is underused in some groups, especially Black or African American patients, leaving gaps in testing infrastructure 3.
• D3 Bio plans trials in US, China, and the European Union (EU). Labs with hospital networks, plus health-tech firms with clinical trial providers, can expand KRAS G12C testing with tissue biopsy (laboratory analysis of tumor tissue; the gold standard) or liquid biopsy (blood-based testing) and add trial sites or patient-finding where testing lags.